Pimozide-d5

Pimozide-d5 (R6238-d5) is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.

1794979-08-0

R6238-d5

12352005

Adrenergic Receptor; Dopamine Receptor; Isotope-Labeled Compounds; STAT

GPCR/G Protein; JAK/STAT Signaling; Neuronal Signaling; Others; Stem Cell/Wnt

Cancer; Endocrinology; Inflammation/Immunology

O=C1N(C2([2H])C([2H])([2H])CN(CC2([2H])[2H])CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C5=CC=CC=C5N1

C28H24D5F2N3O

466.58

[1]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256 (2) :141-7.|[2]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9 (8) :3853-3866. eCollection 2017.|[3]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117 (12) : 3421-3429.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W704363/

Isotope-Labeled Compounds

No Development Reported